[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peter Caravan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100636953","phase-2-advanced-imaging-to-assess-the-effect-of-immunosuppression-on-progressive-fibrosis-100636953",false,"NCT07572383","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Lung Fibrosis in Participants With Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease","Inclusion Criteria:\n\n1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.\n2. Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and \u002F or prednisone for clinically indicated non-IPF ILD treatment.\n3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.\n4. Forced vital capacity (FVC) of \\>\u002F= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) \\>\u002F= 25% predicted on PFTs performed at Visit 1.\n\nExclusion criteria:\n\n1. Current or prior exposure to FDA approved anti-fibrotic therapy.\n2. Extent of emphysema greater than extent of fibrosis.\n3. Pregnancy or plans to become pregnant at baseline or during follow-up.\n4. Contraindications to MRI.\n5. Contraindications to receiving gadolinium-based contrast agents.\n6. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin (only for individuals with a history of chronic kidney disease).\n8. Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.\n9. Respiratory infection within the prior 6 weeks.\n10. Smoking of any kind within the prior 6 months.","ALL","18 Years","80 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \\[68Ga\\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).",[27,28],"Interstitial Lung Disease","Pulmonary Fibrosis","RECRUITING","2026-05-02",{"date":32,"type":33},"2026-05-07","ACTUAL",{"date":35,"type":21},"2026-04",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Peter Caravan","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":41},"100556973","phase-2-advanced-imaging-for-pulmonary-fibrosis-100556973","NCT06532071","Advanced Imaging for Pulmonary Fibrosis","Inclusion Criteria:\n\n1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.\n2. On stable dose immunosuppression treatment (with prednisone, mycophenolate mofetil, mycophenolate sodium, and\u002For rituximab) for at least 3 months.\n3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on HRCT performed within 1 year to or at Visit 1.\n4. FVC of \\>\u002F= 45% and DLCO \\>\u002F= 25% predicted on PFTs performed at Visit 1.\n\nExclusion Criteria:\n\n1. Current or prior exposure to FDA approved anti-fibrotic therapy.\n2. Extent of emphysema greater than extent of fibrosis.\n3. Pregnancy or plans to become pregnant at baseline or during follow-up.\n4. Contraindications to MRI.\n5. Contraindications to receiving gadolinium-based contrast agents.\n6. Research-related radiation exposure exceeds 50 mSv in the prior year.\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin (only for individuals with a history of chronic kidney disease).\n8. Clinically significant PH defined by use of pulmonary vasodilatory therapy.\n9. Respiratory infection within the prior 6 weeks.\n10. Smoking of any kind within the prior 6 months.",{"count":49,"type":21},60,[24],"The purpose of this study is to determine if measurements of active collagen deposition using \\[68Ga\\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.",[28],"2026-04-17",{"date":55,"type":33},"2026-04-22",{"date":57,"type":33},"2025-01-21",{"date":37,"type":21},{"name":39,"class":40},""]